RiNA Acquires Roche's RTS Protein Expression Portfolio | GenomeWeb

NEW YORK (GenomeWeb News) – Berlin-based RiNA has acquired Roche Applied Science's RTS Protein Expression portfolio of cell-free expression kits for an undisclosed sum, Roche said today.

Under the agreement, which takes effect Sept. 15, the firm 5 Prime will serve as RiNA's distributor for the kits, Roche said.

Manfred Baier, who is head of Roche Applied Science, said in a statement that "a company specializing in proteomics will be able to develop the potential of RTS technology much faster than we can."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.